Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Bonnetain

Showing results (1-10 of 161) with videos related to

Pageof 17
Sort By:
Breast (Edinburgh, Scotland)|July 12, 2016
Surrogate end points for overall survival in breast cancer trials: A reviewFrédéric Fiteni, Franck Bonnetain
BMC Cancer|June 12, 2010
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsNicolas Methy, Laurent Bedenne, Franck Bonnetain
Expert Review of Anticancer Therapy|April 13, 2017
Surrogate endpoints for overall survival in lung cancer trials: a reviewFrédéric Fiteni, Virginie Westeel, Franck Bonnetain
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trialsZeinab Hamidou, Tienhan Sandrine Dabakuyo, Franck Bonnetain
Trials|October 14, 2015
Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trialCindy Neuzillet, Mathieu Vergnault, Franck Bonnetain, et al.
BMC Cancer|February 20, 2016
Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical reviewFrédéric Fiteni, Amélie Anota, Virginie Westeel, et al.
Bulletin Du Cancer|March 25, 2015
[Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis]Frédéric Fiteni, Amélie Anota, Virginie Westeel, et al.
Expert Review of Anticancer Therapy|December 13, 2016
Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trialsFrédéric Fiteni, Marie-Justine Paillard, Virginie Westeel, et al.
The Oncologist|February 14, 2013
Factors associated with fatigue after surgery in women with early-stage invasive breast cancerChristine Rotonda, Francis Guillemin, Franck Bonnetain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Survival end point reporting in randomized cancer clinical trials: a review of major journalsSimone Mathoulin-Pelissier, Sophie Gourgou-Bourgade, Franck Bonnetain, et al.
Pageof 17

Showing results (1-10 of 161) with videos related to

Sort By:
Pageof 17
Breast (Edinburgh, Scotland)|July 12, 2016
Surrogate end points for overall survival in breast cancer trials: A reviewFrédéric Fiteni, Franck Bonnetain
BMC Cancer|June 12, 2010
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsNicolas Methy, Laurent Bedenne, Franck Bonnetain
Expert Review of Anticancer Therapy|April 13, 2017
Surrogate endpoints for overall survival in lung cancer trials: a reviewFrédéric Fiteni, Virginie Westeel, Franck Bonnetain
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trialsZeinab Hamidou, Tienhan Sandrine Dabakuyo, Franck Bonnetain
Trials|October 14, 2015
Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trialCindy Neuzillet, Mathieu Vergnault, Franck Bonnetain, et al.
BMC Cancer|February 20, 2016
Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical reviewFrédéric Fiteni, Amélie Anota, Virginie Westeel, et al.
Bulletin Du Cancer|March 25, 2015
[Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis]Frédéric Fiteni, Amélie Anota, Virginie Westeel, et al.
Expert Review of Anticancer Therapy|December 13, 2016
Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trialsFrédéric Fiteni, Marie-Justine Paillard, Virginie Westeel, et al.
The Oncologist|February 14, 2013
Factors associated with fatigue after surgery in women with early-stage invasive breast cancerChristine Rotonda, Francis Guillemin, Franck Bonnetain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Survival end point reporting in randomized cancer clinical trials: a review of major journalsSimone Mathoulin-Pelissier, Sophie Gourgou-Bourgade, Franck Bonnetain, et al.
Pageof 17